Full-year results to 31 March were in line with the trading update at the time of the recent fundraise (£10.5m net), with revenues, adjusted pre-tax loss from the continuing businesses and year-end net debt of £9.8m (+12%), £0.4m and £0.8m, respectively. The company is fully funded to exploit the emerging COVID-19 diagnostic testing opportunities. Despite the disruption to its Food intolerance business in Q1 FY 2021, we still expect strong growth and a profitable FY 20
14 Jul 2020
Omega Diagnostics - FY 2020 results – multiple upcoming newsflow
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - FY 2020 results – multiple upcoming newsflow
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.4 0 0.0% | Mkt Cap: 8.21m
- Published:
14 Jul 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
13
Full-year results to 31 March were in line with the trading update at the time of the recent fundraise (£10.5m net), with revenues, adjusted pre-tax loss from the continuing businesses and year-end net debt of £9.8m (+12%), £0.4m and £0.8m, respectively. The company is fully funded to exploit the emerging COVID-19 diagnostic testing opportunities. Despite the disruption to its Food intolerance business in Q1 FY 2021, we still expect strong growth and a profitable FY 20